通过激素A-PGC1α轴的骨肌内皮功能障碍驱动癌症缓解症的进展
Young-Mee Kim1,2, Mark A Sanborn3, Shaluah Vijeth3
1Department of Biochemistry and Molecular Genetics, University of Illinois College of Medicine, Chicago, IL, USA. youngmee@uic.edu.
Nature cancer
|May 26, 2025
概括
癌症缓冲症是一种衰弱的肌肉消耗状况,与血管功能障碍有关. 恢复肌肉内皮功能和氧酶增殖器激活的受体-γ联合激活器1α (PGC1α) 活性可以保持肌肉质量.
科学领域:
- 在瘤学瘤学.
- 血管生物学 血管生物学
- 肌肉生理学 肌肉生理学
背景情况:
- 癌症缓冲症是一种严重的并发症,其特点是骨肌肉消耗,严重影响患者的生活质量.
- 血管系统功能障碍在调解癌症缓解症中的作用仍然不完全理解.
- 维持足够的肌肉 perfusion 和调节免疫反应是血管系统的关键功能.
研究的目的:
- 为了研究一种假设,即白血病是由血管系统功能障碍介导的假设.
- 确定将瘤进展与肌肉衰竭联系起来的分子机制.
- 探索潜在的治疗策略,针对癌症缓解症的血管完整性.
主要方法:
- 在多种瘤模型中利用透明组织拓来评估肌肉血管密度.
- 在患有癌症可克西亚的患者中量化肌肉血管密度.
- 研究了循环活性蛋白A的作用及其对内皮皮氧化酶增殖器激活受体-γ联合激活剂1α (PGC1α) 表达的作用.
- 在临床前模型中评估了恢复内皮PGC1α活性对肌肉质量的影响.
主要成果:
- 在各种瘤模型 (胰腺腺癌,结肠癌,肺腺癌,黑色素瘤) 中,观察到肌肉血管密度的损失先于肌肉消耗.
- 患有癌症缓冲症的个体表现出肌肉血管密度显著降低.
- 发现循环活性蛋白A水平升高会抑制内皮PGC1α的表达,导致血管泄漏.
- 恢复内皮PGC1α活动成功地保持了瘤携带小鼠的血管密度和肌肉质量.
结论:
- 癌症缓冲症与肌肉血管密度的大量损失有关.
- 瘤诱导的内皮PGC1α表达的抑制是驱动血管泄漏和肌肉衰竭的关键机制.
- 恢复肌肉内皮功能,特别是PGC1α活性,是对抗癌症缓解症的有希望的治疗途径.
更多相关视频
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
7.2K
06:33Author Spotlight: Exploring Orofacial Muscle Regeneration – Insights and Innovations
Published on: December 29, 2023
1.0K
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:17The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
02:53Adaptive Mechanisms in Cancer Cells
6.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
01:35Cancer Cell Migration through Invadopodia
2.4K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.4K
01:24Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
01:22PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K